Exhibit 99.1 CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights Operational Highlights 2025 Full-Year Guidance CEO Commentary "What people want most — a connected, simpler health care experience — is what CVS Health uniquely provides. For the 185 million people we serve, we deliver better access, greater affordability and aligned advocacy. Our strong performance demonstrates the continued focus we have on operational and financial improvement ...

Financial Highlights - Total revenues for the second quarter of 2025 reached $98.9 billion, an increase of 8.4% compared to the prior year [4][7] - Operating income decreased by 21.8% to $2.4 billion, primarily due to $833 million in litigation charges [8] - Adjusted operating income increased by 1.7% to $3.8 billion, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments [8] - Diluted earnings per share (EPS) were $0.80, down from $1.41 in the prior year, while adjusted EPS was $1.81, relatively stable compared to the previous year [4][7] Operational Highlights - The Health Care Benefits segment reported total revenues of $36.3 billion, up from $32.5 billion, with adjusted operating income increasing significantly [10] - The Health Services segment's total revenues rose to $46.5 billion, but adjusted operating income decreased due to litigation charges [12] - The Pharmacy & Consumer Wellness segment saw total revenues increase to $33.6 billion, with adjusted operating income rising significantly [16] 2025 Full-Year Guidance - The company revised its GAAP diluted EPS guidance range to $3.84 to $3.94, down from $4.23 to $4.43 [7] - Adjusted EPS guidance was raised to a range of $6.30 to $6.40, up from $6.00 to $6.20 [7] - Cash flow from operations guidance was increased to at least $7.5 billion, up from approximately $7.0 billion [7] CEO Commentary - The CEO emphasized the company's commitment to providing a connected and simpler health care experience, highlighting strong performance across various segments [1][2] - The focus remains on operational and financial improvement, particularly in the Aetna and CVS Caremark segments [1][5] Additional Insights - The company announced a commitment of $20 billion over the next decade to simplify the U.S. health system [13] - CVS Pharmacy agreed to acquire certain prescription files and store locations from Rite Aid, enhancing its market position [13] - The company is actively working on initiatives to improve the experience for both doctors and patients [13]

Earnings Report - CVS Health is expected to report Q2 earnings of $1.46 per share, a decrease from $1.83 per share in the same period last year [1] - Projected quarterly revenue is $94.59 billion, up from $91.23 billion a year earlier [1] Recent Developments - CVS Health opened a new Workforce Innovation and Talent Center (WITC) in Columbus on July 23 [2] - CVS Health shares increased by 3.8%, closing at $62.30 on Wednesday [2] Analyst Ratings - UBS analyst Kevin Caliendo maintained a Neutral rating and reduced the price target from $71 to $67 [4] - Jefferies analyst Brian Tanquilut maintained a Buy rating and raised the price target from $74 to $80 [4] - Mizuho analyst Ann Hynes maintained an Outperform rating and increased the price target from $70 to $76 [4] - Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 [4]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CVS Health (CVS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. CVS Health is one of 983 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measu ...

Core Insights - CVS Health's Health Care Delivery business has shown strong revenue growth, with a 27% increase in Q1 2025, driven by strategic acquisitions and a focus on value-based care [1][8] Group 1: Financial Performance - The Health Care Delivery segment's revenue growth of 27% in Q1 2025 excludes the impact of exiting certain programs and selling parts of the business [1] - Integration costs related to the acquisitions of Signify Health and Oak Street Health amounted to $45 million in Q1 2025 [2] - CVS Health's Signify unit completed over 3 million in-home health evaluations in 2024, while Oak Street reported a 37% increase in at-risk members [3][8] Group 2: Market Dynamics - The financial performance of the Health Care Delivery business is closely linked to Medicare Advantage medical cost trends, with early signs of pressure observed at Oak Street Health [4] - Humana's CenterWell segment reported a 37.5% revenue growth in Q1 2025, driven by primary care business expansion [5] - Agilon Health is transforming senior healthcare with its PalliUM program, which has seen increased patient participation [6] Group 3: Valuation and Estimates - CVS Health shares have increased by 6.2% over the past six months, contrasting with an 11.6% decline in the industry [7] - The stock is trading at a forward price-to-earnings ratio of 9.06, below the industry average of 14.37, and carries a Value Score of A [9] - Consensus estimates for CVS Health's 2025 earnings have shown an upward trend, with current estimates for Q1 2025 at $1.47 and for the full year at $6.12 [10][11]

Core Insights - CVS Health is set to announce its earnings on July 31, 2025, with historical stock behavior around earnings releases being a key focus for event-driven traders [2] - The consensus estimate for CVS's upcoming earnings is $1.46 per share on revenue of $94.59 billion, indicating a decline in profitability compared to the previous year [4][5] - CVS Health currently has a market capitalization of $76 billion and generated $379 billion in revenue over the last twelve months, with operating profits of $11 billion and net income of $5.3 billion [5] Historical Performance - Over the past five years, CVS stock has shown a tendency toward positive one-day returns post-earnings, with 55% of instances resulting in a positive return and a median gain of 4.4% [3][10] - There have been 20 earnings data points recorded in the last five years, with 11 positive and 9 negative one-day returns observed [6] - The percentage of positive returns increases to 58% when considering data from the last three years [10] Trading Strategies - Traders typically employ pre-earnings positioning, assessing historical probabilities before the earnings report, and post-earnings positioning, observing stock movements after the earnings release [7] - Understanding the correlation between short-term and medium-term returns post-earnings can inform trading strategies, particularly if 1D and 5D returns show high correlation [8][9]

Core Insights - Aetna, a CVS Health company, has launched Aetna Care Paths and AI-driven programs to enhance the healthcare experience for members and providers [1][5] - Aetna Care Paths is a digital tool that provides personalized care recommendations and simplifies the member experience through the Aetna Health app [2][4] Technology Investment - CVS Health is investing $20 billion in digital technology to simplify healthcare navigation, which is a key part of Aetna's strategy [5] - Nearly 50% of active Aetna members use the app monthly to manage their health and understand benefits [5] Aetna Care Paths Features - Aetna Care Paths offers personalized views of benefit information and a dedicated care team for members with specific health conditions [3][4] - AI-driven clinical care summaries can save nurses up to 90 minutes per day, allowing for more quality time with members [6][7] App Enhancements - The Aetna Health app includes features such as vaccine scheduling, a claims cost breakdown chart, AI-powered chat for immediate assistance, and personalized provider recommendations [9][11] - The app also offers advanced accessibility options, including a low-light dark mode interface [9] Company Overview - As of March 31, 2025, CVS Health operates over 9,000 retail pharmacy locations and serves approximately 88 million pharmacy benefits plan members [10] - The company provides health insurance products to over 37 million people, focusing on personalized, technology-driven services to improve health outcomes and reduce costs [10]

Core Insights - CVS Health and UnitedHealth have contrasting first-quarter results, with CVS showing strong growth and raising its full-year EPS guidance, while UnitedHealth missed earnings and revenue expectations, leading to a significant cut in its 2025 EPS outlook [1][19] Group 1: CVS Health Performance - CVS Health's Health Care Benefits segment reported an 8% year-over-year revenue growth in Q1, with medical membership stable at approximately 27.1 million [4] - The adjusted operating income for CVS Health surged to $1.99 billion from $732 million a year ago, driven by the strength in commercial insurance [4][8] - CVS's medical benefit ratio (MBR) improved to 87.3% from 90.4% year-over-year, aided by reserve releases and better Medicare Advantage star ratings [6] Group 2: UnitedHealth Challenges - UnitedHealth's medical care ratio (MCR) increased to 84.8%, up from 84.3% in 2024, due to elevated Medicare Advantage utilization, prompting a cut in 2025 adjusted earnings guidance to $26.00-$26.50 per share [10] - The company is facing significant cost pressures, particularly in outpatient and professional services, which are expected to continue affecting earnings throughout 2025 [10][19] - UnitedHealth's Optum segment saw a 14% year-over-year revenue increase, driven by rising script volumes and specialty pharmacy strength [9] Group 3: Valuation Comparison - CVS is trading at a forward P/E of 8.88X, below its 5-year median of 9.55X, while UnitedHealth is at 11.98X, also below its 5-year median of 19.20X, indicating that CVS is more attractively valued relative to UnitedHealth [16][17] - The Zacks Consensus Estimate for CVS's Q2 2025 EPS suggests a 19.7% decline year-over-year, while UnitedHealth's estimate implies a 28.8% decline [11][14] Group 4: Strategic Initiatives - CVS is conducting a strategic review of Oak Street Health, which it acquired for $10.6 billion, focusing on capital allocation towards higher-return investments [5] - Despite pressures in Medicare Advantage, CVS is positioned as a stronger investment option ahead of Q2 earnings due to its stable commercial insurance performance and disciplined capital management [19]

Core Viewpoint - CVS Health is expected to report a year-over-year decline in earnings despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - CVS Health is projected to post quarterly earnings of $1.47 per share, reflecting a year-over-year decrease of 19.7% [3]. - Revenues are anticipated to reach $93.72 billion, which is a 2.7% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.55% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Most Accurate Estimate for CVS Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.06% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - CVS Health has a Zacks Rank of 2, indicating a strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, CVS Health exceeded the expected earnings of $1.71 per share by delivering $2.25, resulting in a surprise of +31.58% [13]. - Over the past four quarters, CVS Health has consistently beaten consensus EPS estimates [14]. Industry Context - In the Zacks Medical Services industry, Teladoc is expected to report a loss of $0.27 per share, with a year-over-year change of +3.6% [18]. - Teladoc's revenue is projected to be $620.91 million, down 3.4% from the previous year [18]. - The consensus EPS estimate for Teladoc has been revised down by 3.9% in the last 30 days, resulting in an Earnings ESP of -13.8% [19].

Core Insights - CVS Health Corporation is set to report its second-quarter 2025 results on July 31, with adjusted earnings in the last quarter exceeding estimates by 31.58% [1] - The Zacks Consensus Estimate for second-quarter revenues is $93.72 billion, indicating a year-over-year growth of 2.7%, while earnings per share are expected to decline by 19.67% to $1.47 [2][7] Earnings Estimates - Earnings estimates for CVS Health have decreased from $1.58 to $1.47 per share over the past 90 days due to various operational and regulatory challenges [3] - The current earnings estimates for the upcoming quarters are $1.42 for the next quarter, $6.12 for the current year, and $7.00 for the next year [4] Operational Challenges - CVS Health faces operational cost pressures, legal challenges, and regulatory scrutiny, which have negatively impacted earnings estimates [4] - The company has incurred one-time charges totaling $1.082 billion, including $387 million related to the Omnicare verdict and $448 million in ACA-related reserves [4] Segment Performance - The Health Care Benefits segment is expected to generate revenues of $34.6 billion, with a focus on margin recovery through benefit redesigns and pricing changes [6][8] - The Pharmacy & Consumer Wellness segment is projected to achieve revenues of $32.16 billion, benefiting from increased prescription volumes despite reimbursement pressures [11][12] - The Health Services segment is estimated to generate $43.52 billion in revenues, supported by the performance of Caremark, CVS's pharmacy benefit manager [10][9] Stock Performance - CVS Health shares gained 2.5% in the second quarter of 2025, underperforming the S&P 500's 10.7% rise [13] - Compared to peers, CVS outperformed Herbalife and UnitedHealth Group, which saw declines of 2.2% and 40% respectively [13] Valuation - CVS Health's forward 12-month price-to-earnings (P/E) ratio is 9.24X, which is a premium compared to Herbalife's 4.51X but undervalued relative to UnitedHealth's 12.27X [16] Strategic Initiatives - CVS is implementing strategies to improve profitability, including redesigning Aetna benefits and enhancing drug pricing transparency through new PBM models [17] - The company is also optimizing its retail footprint and has plans to close over 20 pharmacies in Arkansas due to new regulatory laws [4][5]